Zacks Research Brokers Lift Earnings Estimates for Novartis AG (NYSE:NVS)

Novartis AG (NYSE:NVS) – Research analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Novartis in a note issued to investors on Monday, September 30th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.93 per share for the quarter, up from their previous forecast of $1.92. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.20 EPS and FY2025 earnings at $8.26 EPS.

Other equities research analysts have also issued reports about the company. Bank of America cut Novartis from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $135.00 to $130.00 in a report on Wednesday, September 11th. Barclays raised shares of Novartis to a “strong sell” rating in a research report on Monday, June 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Jefferies Financial Group lowered Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $121.00 price objective (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $120.70.

Novartis Trading Down 0.4 %

Shares of NVS opened at $114.53 on Wednesday. Novartis has a fifty-two week low of $92.19 and a fifty-two week high of $120.92. The stock has a market capitalization of $234.10 billion, a PE ratio of 15.46, a P/E/G ratio of 1.73 and a beta of 0.57. The company’s fifty day moving average is $115.17 and its 200 day moving average is $106.30. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The firm had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same quarter in the previous year, the firm posted $1.83 EPS.

Hedge Funds Weigh In On Novartis

Several institutional investors have recently modified their holdings of the business. Founders Financial Securities LLC increased its stake in Novartis by 3.4% in the second quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock valued at $301,000 after purchasing an additional 94 shares during the last quarter. NBC Securities Inc. lifted its position in Novartis by 0.9% in the second quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock valued at $1,116,000 after acquiring an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Novartis by 5.1% in the first quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock valued at $196,000 after acquiring an additional 98 shares during the last quarter. Portside Wealth Group LLC grew its holdings in shares of Novartis by 3.4% during the second quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock worth $319,000 after purchasing an additional 99 shares during the last quarter. Finally, Evermay Wealth Management LLC increased its position in shares of Novartis by 9.3% during the first quarter. Evermay Wealth Management LLC now owns 1,176 shares of the company’s stock worth $114,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.